CellCeutix pharmaceutical company

AUSTIN, Texas--(BUSINESS WIRE)--SmallCapVoice.com, Inc. announced today that a new audio interview with Cellceutix Corporation (OTCBB: CTIX - News), an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs, is now available. The interview can be heard at http://smallcapvoice.com/blog/10-5-09-audio-interview-with-cellceutix-corp-otcbb-ctix.

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and investor fact sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

About Cellceutix Corp.:

Headquartered in Beverly, Mass., Cellceutix is an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs. It owns the rights to seven drug compounds, including Kevetrin, which it is developing as a treatment for certain drug resistant cancers, and KM-133, which it is developing for psoriasis. For more information, visit: www.cellceutix.com.

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In light of these uncertainties the forward-looking events referred to in this release might not occur.